Site activation delays cost trials time and trust. ICON’s new whitepaper shows how human-centred strategies accelerate startup and improve site satisfaction. Download now: https://ow.ly/j6RK50XB6ZW
About us
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
External link for ICON plc
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Dublin
- Type
- Public Company
- Specialties
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs, and Global Patient Insights & Engagement
Locations
Employees at ICON plc
Updates
-
USP compounding may be fast — but is it costing you quality, compliance, and insight? In this insightful session, our experts discussed: - Why GMP manufacturing offers a strategic edge in early phase trials - Real-world case studies where USP compounding fell short - Optimised GMP facility design Listen to the recording to discover how GMP manufacturing can improve trial outcomes, reduce risk, and support regulatory success. https://ow.ly/M8Qh50XyFIU
-
-
For medical device developers selecting the right AI model and data is crucial to capitalise on this powerful technology. Our new whitepaper explains best practices for AI-enabled devices. Learn about AI models, datasets and preparing for FDA Pre-Subs. https://ow.ly/B0N950XAzbv
-
-
Attending #ASH25? Stop by booth #2161 to meet the ICON team and discuss how our extensive testing capabilities, clinical research experience and scientific expertise can support global oncology and haematology research programmes. https://ow.ly/PuyR50XkiX2
-
-
ICON was amongst several leading Irish businesses that participated in the first Ireland-Ukraine Economic Forum: https://lnkd.in/eQmATh-f
-
-
The CRA role is evolving—from data checker to strategic partner. ICON’s Helen Yeardley explores how technology is reshaping clinical trial oversight. Read the Applied Clinical Trials article: https://ow.ly/paW350XB6R6
-
-
Because existing HIV therapies are already highly effective when taken as prescribed, traditional trial settings often fail to reveal the added value of emerging approaches. Explore how developers can plan trials that demonstrate the true advantages and utility of an HIV intervention in the article from ICON. https://ow.ly/1NzU50XAB5s
-
-
Meet ICON’s experts at #ASH25, booth #2161 to discuss how our extensive testing capabilities, clinical research experience and scientific expertise can support global oncology and haematology research programmes. https://ow.ly/PuyR50XkiX2
-
-
Tomorrow, 6 December, is the final day of the SCDM #INDIA25! ICON’s experts have been sharing insights in sessions covering clinical trials and data management, regulatory affairs, biotech and pharma partnerships, real-world evidence, and medical technology innovation. Don’t miss your last chance to attend their sessions and visit us at booth #22 to connect in person. https://lnkd.in/gY_VWm5Z
-
-
While RWD and tokenisation introduce many efficiencies and benefits to long-term follow-up, there are also extremely stringent requirements for handling the associated data. Find out how to ensure secure long-term follow-up for your vaccine, including regulatory considerations, informed consent, and data privacy, in our new whitepaper. https://ow.ly/fHEc50XyWjv
-